Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
EBITDAEPS (Basic)EPS (Weighted Average and Diluted)Interest & Investment IncomeInterest ExpensesInterest ExpensesNon Operating IncomeOperating ExpensesOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Achieve Life Sciences (ACHV) Operating Expenses (2016 - 2026)

Achieve Life Sciences (ACHV) has disclosed Operating Expenses for 17 consecutive years, with $10.5 million as the latest value for Q1 2026.

  • Quarterly Operating Expenses fell 18.85% to $10.5 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $52.4 million through Mar 2026, up 14.07% year-over-year, with the annual reading at $54.9 million for FY2025, 40.47% up from the prior year.
  • Operating Expenses for Q1 2026 was $10.5 million at Achieve Life Sciences, down from $14.7 million in the prior quarter.
  • The five-year high for Operating Expenses was $14.7 million in Q4 2025, with the low at $4.4 million in Q4 2023.
  • Average Operating Expenses over 5 years is $10.1 million, with a median of $10.5 million recorded in 2026.
  • The sharpest move saw Operating Expenses crashed 59.62% in 2023, then soared 177.93% in 2024.
  • Achieve Life Sciences' Operating Expenses stood at $10.9 million in 2022, then plummeted by 59.62% to $4.4 million in 2023, then soared by 177.93% to $12.2 million in 2024, then rose by 20.84% to $14.7 million in 2025, then dropped by 28.97% to $10.5 million in 2026.
  • Per Business Quant, the three most recent readings for ACHV's Operating Expenses are $10.5 million (Q1 2026), $14.7 million (Q4 2025), and $14.7 million (Q3 2025).